Skip to content
Subscriber Only
Business

Biogen’s Alzheimer’s Drug Data Encouraging, Not ‘Shock and Awe’

  • Treatment slowed progression of disease by 30% at highest dose
  • Doctors say more information is needed to confirm benefits
Biogen, Eisai’s Alzheimer’s Drug E2609 to Enter Late-Stage Trial

Photographer: Scott Eisen/Bloomberg

Updated on

Eisai Co.’s market value plunged by $2.7 billion Thursday as investors were disappointed with test results for an experimental Alzheimer’s disease drug from the Japanese company and Biogen Inc.

Results showing the treatment slowed progression of the disease by 30 percent fell short of expectations that had sent Eisai soaring earlier this month after it announced initial test results showing promise for the drug. After the data was released Wednesday, doctors and patient advocates said more information was needed from larger, longer studies.